WorldCat Identities

Köppen, Hartmut

Overview
Works: 12 works in 23 publications in 3 languages and 62 library holdings
Genres: Fiction 
Roles: Author
Classifications: PT2711.O674, 616.33
Publication Timeline
.
Most widely held works by Hartmut Köppen
Gastroenterologie für die Praxis : 51 Tabellen by Hartmut Köppen( Book )

5 editions published in 2010 in German and held by 32 WorldCat member libraries worldwide

Pirx von Tolem : Fantasyroman by Hartmut Köppen( )

1 edition published in 2018 in German and held by 11 WorldCat member libraries worldwide

Pirx von Tolem gelang es zusammen mit seiner Kampfgefährtin Hora-N, seinem Freund Aaron und vielen neuen Verbündeten die Menschheit zu mobilisieren und den Imperator zu stürzen. Auf ihrem Weg fanden sie immer wieder Spuren riesenhafter menschenähnlicher Gestalten, welche sie die Schöpfer oder Erschaffer nennen. Auch auf der alten Erde berichtet die Bibel über sie. Dort heißt es: „In jenen Tagen waren die Riesen auf der Erde, und auch später noch, solange die Gottessöhne zu den Töchtern der Menschen kamen, und diese ihnen Kinder gebaren .“ (1. Moses 6,4) Wenn sie wirklich in der Vergangenheit die Erde besuchten, gibt es sie noch? Was ist mit den mysteriösen Kugeln, die ihren Träger zu ungeahnten Fähigkeiten verhelfen? Pirx und seine Freunde gehen auf eine neue abenteuerliche und gefährliche Reise, um die offenen Fragen zu klären. Auf der Erde bemühen sich Lord Richard und sein Sohn Georg Pirxs Kampf weiter zu führen, aber sie haben mächtige Feinde. Die Ereignisse überschlagen sich und spitzen sich zu. Alle Augen ruhen wieder auf Pirx. Wird er es erneut schaffen, sich gegen überlegene Gegner zu behaupten ? Doch die Menschheit steht vor einem noch viel ernsteren Problem. Unbarmherzig nähert sich die Flotte der Insektoiden. Der Krieg war noch lange nicht vorbei, sondern sollte gerade erst beginnen
Pirx von Tolem Endstation Himmelreich by Hartmut Köppen( Book )

4 editions published between 2014 and 2018 in German and held by 4 WorldCat member libraries worldwide

Entscheidungen zum Leistungsprofil einer stationären Inneren Abteilung : Unters. im Kreiskrankenhaus Templin by Hartmut Köppen( )

3 editions published between 1986 and 1987 in German and held by 3 WorldCat member libraries worldwide

Bestimmung von Plasma-Kallikrein mit einem chromogenen Peptidsubstrat : Methodik u. klin. Anwendung by Hartmut Koeppen( Book )

2 editions published in 1980 in German and held by 3 WorldCat member libraries worldwide

Pirx von Tolem - Großdruck Endstation Himmelreich by Hartmut Köppen( Book )

2 editions published between 2014 and 2018 in German and held by 2 WorldCat member libraries worldwide

Untere Darmblutung Sonderauszugsausgabe aus Gastroenterologie für die Praxis ; 8 Tabellen by Hartmut Köppen( Book )

1 edition published in 2010 in German and held by 2 WorldCat member libraries worldwide

Atlas de gastroenterologie practică 346 de ilustraţii, 51 de tabele by Hartmut Köppen( Book )

1 edition published in 2015 in Romanian and held by 1 WorldCat member library worldwide

Tipping point der Weg in eine bessere Gesellschaft by Hartmut Köppen( )

1 edition published in 2014 in German and held by 1 WorldCat member library worldwide

A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract: Background: Dysregulated hepatocyte growth factor/mesenchymal‐epithelial transition (MET) signaling is associated with poor prognosis and resistance to vascular endothelial growth factor inhibition in metastatic colorectal cancer (mCRC). We report outcomes from a double‐blind, multicenter phase II trial of the MET inhibitor onartuzumab in combination with mFOLFOX‐6 and bevacizumab for mCRC (GO27827; NCT01418222). Materials and Methods: Patients were randomized 1:1 to receive onartuzumab (10 mg/kg intravenously [IV]) or placebo plus mFOLFOX‐6 and bevacizumab (5 mg/kg IV). Oxaliplatin was given for 8–12 cycles; other agents were continued until disease progression, unacceptable toxicity, or death. The primary endpoint was progression‐free survival (PFS) in the intent‐to‐treat (ITT) and MET immunohistochemistry (IHC) expression‐positive populations. Results: Between September 2011 and November 2012, 194 patients were enrolled. In September 2013, an interim analysis recommended stopping onartuzumab treatment due to lack of efficacy. At the time of the final analysis in February 2014, no significant improvement in PFS was seen with onartuzumab versus placebo in either the ITT or MET IHC‐positive populations. An improvement in PFS was noted in the MET IHC‐negative population. Neither overall survival nor response rate was improved with onartuzumab. The incidence of fatigue, peripheral edema, and deep vein thrombosis was increased with onartuzumab relative to placebo. Conclusion: Onartuzumab combined with mFOLFOX‐6 and bevacizumab did not significantly improve efficacy outcomes in either the ITT or MET IHC‐positive populations. MET expression by IHC was not a predictive biomarker in this setting. The Oncologist 2017;22:264–271 Implications for Practice: The addition of onartuzumab to mFOLFOX‐6 plus bevacizumab did not improve outcomes in patients with previously untreated metastatic colorectal cancer in this randomized, phase II study. Although initial results with onartuzumab were promising, a number of phase II/III clinical trials have reported a lack of improvement in efficacy with onartuzumab combined with standard‐of‐care therapies in several tumor types. Furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal‐epithelial transition (MET) receptor. MET immunohistochemistry was not a predictive biomarker. It remains to be seen if other biomarkers or small molecule inhibitors may be more appropriate for inhibiting this oncogenic pathway. Abstract : Treatment for advanced metastatic colorectal cancer has improved over the past decade with the addition of biologic agents to standard chemotherapy regimens, leading to increases in median overall survival. FOLFOX plus bevacizumab is now widely accepted as the standard first‐line treatment. To determine whether onartuzumab has a beneficial role in either unselected or MET‐selected populations with metastatic colorectal cancer, this phase II study was initiated to evaluate the combination of bevacizumab and mFOLOFOX6 with or without onartuzumab
Profiling Cancer Gene Mutations in Clinical Formalin‐Fixed, Paraffin‐Embedded Colorectal Tumor Specimens Using Targeted Next‐Generation Sequencing( )

1 edition published in 2014 in English and held by 1 WorldCat member library worldwide

Abstract : Purpose: The success of precision oncology relies on accurate and sensitive molecular profiling. The Ion AmpliSeq Cancer Panel, a targeted enrichment method for next‐generation sequencing (NGS) using the Ion Torrent platform, provides a fast, easy, and cost‐effective sequencing workflow for detecting genomic "hotspot" regions that are frequently mutated in human cancer genes. Most recently, the U.K. has launched the AmpliSeq sequencing test in its National Health Service. This study aimed to evaluate the clinical application of the AmpliSeq methodology. Methods: We used 10 ng of genomic DNA from formalin‐fixed, paraffin‐embedded human colorectal cancer (CRC) tumor specimens to sequence 46 cancer genes using the AmpliSeq platform. In a validation study, we developed an orthogonal NGS‐based resequencing approach (SimpliSeq) to assess the AmpliSeq variant calls. Results: Validated mutational analyses revealed that AmpliSeq was effective in profiling gene mutations, and that the method correctly pinpointed "true‐positive" gene mutations with variant frequency >5% and demonstrated high‐level molecular heterogeneity in CRC. However, AmpliSeq enrichment and NGS also produced several recurrent "false‐positive" calls in clinically druggable oncogenes such as PIK3CA . Conclusion: AmpliSeq provided highly sensitive and quantitative mutation detection for most of the genes on its cancer panel using limited DNA quantities from formalin‐fixed, paraffin‐embedded samples. For those genes with recurrent "false‐positive" variant calls, caution should be used in data interpretation, and orthogonal verification of mutations is recommended for clinical decision making. Abstract : The authors used 10 ng of genomic DNA from formalin‐fixed, paraffin‐embedded human colorectal cancer tumors to sequence 46 cancer genes using the AmpliSeq platform. They developed an orthogonal resequencing approach, SimpliSeq, to evaluate the clinical application of AmpliSeq. The results suggest that AmpliSeq provides highly sensitive and quantitative mutation detection for most genes on its cancer panel; however, verification testing is critical for low‐abundance variants and genes that are found to have recurrent false‐positive variants
Bestimmung von Plasma - Kallikrein mit einem chromogenen Peptidsubstrat - Methodik und Klinische Anwendung by Hartmut Koeppen( )

1 edition published in 1981 in German and held by 1 WorldCat member library worldwide

 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.86 (from 0.55 for Pirx von T ... to 0.97 for Atlas de g ...)

Alternative Names
Koeppen, Hartmut 1957-

Languages